Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

INTRODUCTION: This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM) in the USA. RESEARCH DESIGN AND METHODS: A re...

Descripción completa

Detalles Bibliográficos
Autores principales: Singhal, Mukul, Tan, Hiangkiat, Coleman, Craig I, Han, Michelle, Nguyen, Chi, Ingham, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Epidemiology/Health Services Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861096/
https://www.ncbi.nlm.nih.gov/pubmed/31798890
http://dx.doi.org/10.1136/bmjdrc-2019-000704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861096/
https://www.ncbi.nlm.nih.gov/pubmed/31798890
http://dx.doi.org/10.1136/bmjdrc-2019-000704

Ejemplares similares